Your session is about to expire
← Back to Search
Procedure
IRE + MRgRT for Prostate Cancer (RTIRE Trial)
N/A
Recruiting
Led By Timothy McClure
Research Sponsored by Weill Medical College of Cornell University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Men aged ≥ 18
Gland size < 80 cc
Must not have
Prior TURP.
Prior history of receiving pelvic radiotherapy.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, every 3 months (up to 60 months)
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new combined treatment for prostate cancer that is hoped to be both effective and safe.
Who is the study for?
Men over 18 with intermediate risk prostate cancer, specifically grade group 2 or 3 as seen in MRI. They must be able to undergo IRE and MRgRT treatments, have a prostate gland size under 80 cc, an ECOG performance status of 0-1 (fully active or restricted in physically strenuous activity), and agree to follow-up biopsies. Excluded are those with metastatic cancer, prior pelvic radiotherapy or focal therapy, inflammatory bowel disease, TURP history, general anesthesia risks, or urethral strictures.
What is being tested?
The trial is testing the combination of Irreversible Electroporation (IRE) and Magnetic Resonance guided Radiotherapy (MRgRT) on men with intermediate risk prostate cancer. The goal is to see if this combined treatment can be done safely with low side effects while being effective for patients who meet specific criteria.
What are the potential side effects?
While not explicitly listed here, potential side effects may include discomfort from the procedure itself like bruising or bleeding at the needle insertion site for IRE; skin irritation from radiation; fatigue; urinary issues such as frequency and urgency due to proximity to bladder; erectile dysfunction due to nerve damage.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a man aged 18 or older.
Select...
My gland is smaller than 80 cc.
Select...
I am fit for IRE treatment.
Select...
My prostate cancer is at an intermediate stage, according to NCCN guidelines.
Select...
I am willing to have a biopsy after 12 months.
Select...
My MRI shows I have a moderate-grade prostate cancer.
Select...
I can undergo MRI-guided radiotherapy.
Select...
My MRI shows a specific type of prostate cancer (grade group 2).
Select...
I am fully active or have some restrictions but can still care for myself.
Select...
My prostate cancer is at an intermediate risk level.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had a prostate surgery known as TURP.
Select...
I have had radiation therapy to my pelvic area before.
Select...
I have had targeted treatment for a specific area of my body.
Select...
I cannot have surgery that requires being put to sleep.
Select...
I have had a narrowing of my bladder neck or urethra.
Select...
I cannot be positioned for certain medical procedures due to physical limitations.
Select...
I have prostate cancer that has spread to other parts of my body.
Select...
I have a history of inflammatory bowel disease.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, every 3 months (up to 60 months)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, every 3 months (up to 60 months)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Feasibility as measured by percentage of subjects assessed at 12 weeks post-IRE
Feasibility as measured by percentage of subjects assessed at 6 weeks post-MRgRT within 1 year
Secondary study objectives
Change in Impact of RTIRE on health-related quality of life as measured by International Index of Erectile Function (IIEF-5)
Change in Impact of RTIRE on health-related quality of life as measured by the International Prostate Symptom Score (IPSS)
Prostate Specific Antigen
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Irreversible Electroporation and RadiotherapyExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
Weill Medical College of Cornell UniversityLead Sponsor
1,081 Previous Clinical Trials
1,137,997 Total Patients Enrolled
19 Trials studying Prostate Cancer
27,955 Patients Enrolled for Prostate Cancer
Timothy McClurePrincipal InvestigatorWeill Medical College of Cornell University
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am a man aged 18 or older.I have had a prostate surgery known as TURP.My gland is smaller than 80 cc.I am fit for IRE treatment.I have had radiation therapy to my pelvic area before.I have had targeted treatment for a specific area of my body.I cannot have surgery that requires being put to sleep.I have had a narrowing of my bladder neck or urethra.My prostate cancer is at an intermediate stage, according to NCCN guidelines.I cannot be positioned for certain medical procedures due to physical limitations.I am willing to have a biopsy after 12 months.I have prostate cancer that has spread to other parts of my body.My MRI shows I have a moderate-grade prostate cancer.I can undergo MRI-guided radiotherapy.My MRI shows a specific type of prostate cancer (grade group 2).I am fully active or have some restrictions but can still care for myself.My prostate cancer is at an intermediate risk level.I have a history of inflammatory bowel disease.
Research Study Groups:
This trial has the following groups:- Group 1: Irreversible Electroporation and Radiotherapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger